JP2018502924A - 静脈内バクロフェン製剤および治療方法 - Google Patents

静脈内バクロフェン製剤および治療方法 Download PDF

Info

Publication number
JP2018502924A
JP2018502924A JP2017556780A JP2017556780A JP2018502924A JP 2018502924 A JP2018502924 A JP 2018502924A JP 2017556780 A JP2017556780 A JP 2017556780A JP 2017556780 A JP2017556780 A JP 2017556780A JP 2018502924 A JP2018502924 A JP 2018502924A
Authority
JP
Japan
Prior art keywords
baclofen
oral
administration
dose
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017556780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502924A5 (enExample
Inventor
クロイド ジム
クロイド ジム
ゴメツ アドルフォ
ゴメツ アドルフォ
クラッチ リンダ
クラッチ リンダ
クリエル ロバート
クリエル ロバート
シュロギー ジョン
シュロギー ジョン
タッカー ステファン
タッカー ステファン
テューイ ロブ
テューイ ロブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allaysis LLC
Original Assignee
Allaysis LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allaysis LLC filed Critical Allaysis LLC
Publication of JP2018502924A publication Critical patent/JP2018502924A/ja
Publication of JP2018502924A5 publication Critical patent/JP2018502924A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017556780A 2015-01-15 2016-01-15 静脈内バクロフェン製剤および治療方法 Pending JP2018502924A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562103902P 2015-01-15 2015-01-15
US62/103,902 2015-01-15
PCT/US2016/013672 WO2016115504A1 (en) 2015-01-15 2016-01-15 Intravenous baclofen formulations and treatment methods

Publications (2)

Publication Number Publication Date
JP2018502924A true JP2018502924A (ja) 2018-02-01
JP2018502924A5 JP2018502924A5 (enExample) 2019-02-28

Family

ID=56406482

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017556780A Pending JP2018502924A (ja) 2015-01-15 2016-01-15 静脈内バクロフェン製剤および治療方法

Country Status (6)

Country Link
US (5) US10350183B2 (enExample)
EP (1) EP3244884A4 (enExample)
JP (1) JP2018502924A (enExample)
CA (1) CA2974091A1 (enExample)
MX (1) MX2017009313A (enExample)
WO (1) WO2016115504A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023530769A (ja) * 2020-06-22 2023-07-19 オティビオ・エーエス 鎮痙組成物および陰圧療法を用いて痙縮を治療するための方法
JP2024501259A (ja) * 2020-12-24 2024-01-11 アレイシス、 エルエルシー 静脈内バクロフェンの投与方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350183B2 (en) 2015-01-15 2019-07-16 Allaysis, Llc Intravenous baclofen formulations and treatment methods
MX2018004656A (es) * 2015-10-21 2019-01-10 Allaysis Llc Baclofeno intravenoso y metodos de tratamiento.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510314A (ja) * 2006-11-22 2010-04-02 シーサイド セラピューティクス，エルエルシー 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法
US20130109755A1 (en) * 2011-10-27 2013-05-02 Medtronic, Inc. Baclofen Formulations and Methods for Making Same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH26730A (en) 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
EP0461958B1 (fr) 1990-06-15 1994-09-14 Synthelabo Dérivés de 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxanes, leur préparation et leur application en thérapeutique
IT1319275B1 (it) * 1999-10-08 2003-09-26 Neuroscienze S C A R L Uso del baclofen nel trattamento dell'astinenza da etanolo.
US6969383B2 (en) 2002-09-27 2005-11-29 Medtronic, Inc. Method for treating severe tinnitus
WO2005037215A2 (en) * 2003-10-14 2005-04-28 Massachusetts Institute Of Technology Compositions and methods for enhancing cognitive function and synaptic plasticity
US7824697B2 (en) * 2004-07-12 2010-11-02 Board Of Regents, The University Of Texas System High concentration baclofen preparations
US9622997B2 (en) * 2012-06-01 2017-04-18 Lynn Health Science Institute, Inc. Methods for treating insomnia
US10350183B2 (en) 2015-01-15 2019-07-16 Allaysis, Llc Intravenous baclofen formulations and treatment methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510314A (ja) * 2006-11-22 2010-04-02 シーサイド セラピューティクス，エルエルシー 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法
US20130109755A1 (en) * 2011-10-27 2013-05-02 Medtronic, Inc. Baclofen Formulations and Methods for Making Same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL OF NEUROSURGERY, vol. 22, JPN6019039784, 2008, pages 508 - 519, ISSN: 0004136144 *
JOURNAL OF PEDIATRIC REHABILITATION MEDICINE, vol. 4, JPN6019039781, 2011, pages 89 - 98, ISSN: 0004136143 *
JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 66, JPN6019039778, 2014, pages 935 - 942, ISSN: 0004262649 *
PHYSICAL MEDICINE AND REHABILITATION, vol. Vol.6(9S), JPN6019039777, 2014, pages 221 - 222, ISSN: 0004262648 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023530769A (ja) * 2020-06-22 2023-07-19 オティビオ・エーエス 鎮痙組成物および陰圧療法を用いて痙縮を治療するための方法
JP7586521B2 (ja) 2020-06-22 2024-11-19 オティビオ・エーエス 鎮痙組成物および陰圧療法を用いて痙縮を治療するための方法
JP2024501259A (ja) * 2020-12-24 2024-01-11 アレイシス、 エルエルシー 静脈内バクロフェンの投与方法

Also Published As

Publication number Publication date
CA2974091A1 (en) 2016-07-21
US20190388373A1 (en) 2019-12-26
EP3244884A4 (en) 2018-07-25
US20230248679A1 (en) 2023-08-10
US10350183B2 (en) 2019-07-16
WO2016115504A1 (en) 2016-07-21
EP3244884A1 (en) 2017-11-22
US20160213631A1 (en) 2016-07-28
MX2017009313A (es) 2018-02-09
US10933042B2 (en) 2021-03-02
US12295929B2 (en) 2025-05-13
US20210228520A1 (en) 2021-07-29
US20200038353A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
US12295929B2 (en) Intravenous baclofen formulations and treatment methods
RU2519660C2 (ru) Режим дозировки селективного агониста рецептора s1p1
RU2012117563A (ru) Режим дозирования модулятора рецептора s1p
Schechtmann et al. Intrathecal clonidine and baclofen enhance the pain-relieving effect of spinal cord stimulation: a comparative placebo-controlled, randomized trial
Konai et al. Monoarticular corticosteroid injection versus systemic administration in the treatment of rheumatoid arthritis patients: a randomized double-blind controlled study
KR20170057435A (ko) 궤양성 대장염의 치료용 의약 조성물
US7393857B2 (en) Use of 5-HT3 receptor antagonists for treating musculoskeletal diseases
JP2018522941A (ja) セバコイルジナルブフィンエステルの徐放のための医薬製剤
AU2025242078A1 (en) Drug delivery formulations
JP2018502924A5 (enExample)
CN1291718C (zh) 一种用于治疗急性心肌梗死的药物产品
RU2322238C2 (ru) Лечение ревматоидного артрита
JP2005526022A5 (ja) 関節リウマチの処置
JP2018531271A (ja) 静脈内バクロフェン及び治療方法
JP2018531271A6 (ja) 静脈内バクロフェン及び治療方法
EP3784243B1 (en) Methotrexate for use as a medicament
Metz et al. Greater Immediate Gastric Acid Suppression with Lansoprazole 30 mg Administered as a 2‐Minute Intravenous Bolus Injection versus a 30‐Minute Infusion
Hirata et al. Hypoglycemic coma induced by the use of succinic acid cibenzoline in frail late-stage elderly subjects
WO2022212813A1 (en) Subcutaneous infusion of furosemide
EP3965732A1 (en) Pharmaceutical compositions for treating presbyopia and methods for fabricating thereof
Briggs et al. 380 INITIAL RESULTS OF TREATMENT WITH HYLAN GF 20 AND CORTICOSTEROID
Jamadar et al. A Comparative study of Triamcinolone acetonic with Methylprednisolone sodium succinate in the management of chronic low back pain
Hayek et al. Complex Regional Pain Syndrome (CRPS)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200123

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200519